| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $238 | 1 | 33 |
Sells | $241 | 2 | 67 |
| Jin David | director | 1 | $238 | 0 | $0 | $238 |
| Chill Adam J. | director | 0 | $0 | 1 | $4 | $-4 |
| Herskowitz Neil | director | 0 | $0 | 1 | $238 | $-238 |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an …
Over the last 12 months, insiders at Mustang Bio, Inc. have bought $238 and sold $241 worth of Mustang Bio, Inc. stock.
On average, over the past 5 years, insiders at Mustang Bio, Inc. have bought $6,061 and sold $4,123 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Jin David (director) — $238.
The last purchase of 247 shares for transaction amount of $238 was made by Jin David (director) on 2025‑12‑30.
| 2025-12-30 | Sale | Chill Adam J. | director | 4 <0.0001% | $0.95 | $4 | -26.31% | |
| 2025-12-30 | Sale | Herskowitz Neil | director | 247 0.0034% | $0.96 | $238 | -26.31% | |
| 2025-12-30 | Jin David | director | 247 0.0034% | $0.96 | $238 | -26.31% | ||
| 2022-09-13 | Litchman Manuel MD | director | 5,000 0.0041% | $0.52 | $2,582 | -30.68% | ||
| 2022-09-13 | ROSENWALD LINDSAY A MD | director | 5,000 0.0041% | $0.52 | $2,582 | -30.68% | ||
| 2022-03-18 | Litchman Manuel MD | director | 5,000 0.0041% | $0.74 | $3,695 | -34.11% | ||
| 2022-03-18 | ROSENWALD LINDSAY A MD | director | 4,094 0.0034% | $0.74 | $3,025 | -34.11% | ||
| 2021-12-14 | Sale | Achenbach Brian | SVP, Fin. & Corp. Controller | 4,374 0.0003% | $1.83 | $8,004 | -62.80% | |
| 2021-10-27 | Litchman Manuel MD | President and CEO | 65,000 0.0048% | $2.24 | $145,600 | -65.88% | ||
| 2021-10-12 | Sale | Achenbach Brian | SVP, Fin. & Corp. Controller | 4,450 0.0003% | $2.28 | $10,146 | -64.93% | |
| 2021-07-30 | Litchman Manuel MD | President and CEO | 86,206 0.0063% | $2.91 | $250,859 | -59.52% | ||
| 2021-04-09 | Sale | Achenbach Brian | SVP, Fin. & Corp. Controller | 2,423 0.0002% | $3.36 | $8,141 | -22.88% | |
| 2021-03-05 | Litchman Manuel MD | President and CEO | 165,562 0.0135% | $3.12 | $516,553 | -12.46% | ||
| 2020-12-15 | Litchman Manuel MD | President and CEO | 100,000 0.0114% | $2.91 | $291,000 | +2.69% | ||
| 2020-12-14 | ROSENWALD LINDSAY A MD | director | 100,000 0.0115% | $2.66 | $266,000 | +12.96% | ||
| 2020-12-08 | Sale | Achenbach Brian | SVP, Fin. & Corp. Controller | 5,185 0.0006% | $3.03 | $15,711 | -1.29% | |
| 2020-10-21 | Sale | Achenbach Brian | SVP, Fin. & Corp. Controller | 3,056 0.0004% | $2.97 | $9,076 | +11.39% | |
| 2020-06-11 | Litchman Manuel MD | President and CEO | 153,846 0.0228% | $3.25 | $500,000 | +0.15% | ||
| 2020-05-22 | Sale | Litchman Manuel MD | President and CEO | 12,373 0.0018% | $3.04 | $37,614 | +5.84% | |
| 2020-05-22 | Sale | Achenbach Brian | SVP, Fin. & Corp. Controller | 880 0.0001% | $3.04 | $2,675 | +5.84% |
| Jin David | director | 286 0.0042% | $117.09 | 1 | 0 | |
| Herskowitz Neil | director | 145 0.0022% | $59.36 | 1 | 1 | |
| Litchman Manuel MD | director | 1098987 16.3245% | $449,925.28 | 14 | 1 | +1.42% |
| ROSENWALD LINDSAY A MD | director | 299181 4.4441% | $122,484.70 | 4 | 0 | +12.96% |
| Achenbach Brian | SVP, Fin. & Corp. Controller | 144729 2.1498% | $59,252.05 | 3 | 8 |
$6,974,678 | 45 | -14.98% | $4.63M | |
$633,070 | 27 | -5.89% | $2.04M | |
$8,249,886 | 17 | -47.87% | $399,787.00 | |
$117,515 | 16 | -27.38% | $1.66M | |
$24,098 | 12 | -21.64% | $1.44M |
| Increased Positions | 12 | +57.14% | 284,301 | +101.31% |
| Decreased Positions | 6 | -28.57% | 12,981 | -4.63% |
| New Positions | 6 | New | 225,698 | New |
| Sold Out Positions | 3 | Sold Out | 12,431 | Sold Out |
| Total Postitions | 27 | +28.57% | 551,955 | +96.68% |
| Blackrock, Inc. | $91.00 | 1.41% | 84,745 | +83,080 | +4,989.79% | 2025-09-30 |
| Kestra Advisory Services, Llc | $71.00 | 1.1% | 66,108 | +66,108 | New | 2025-09-30 |
| Vanguard Group Inc | $62.00 | 0.96% | 57,863 | +57,863 | New | 2025-09-30 |
| Geode Capital Management, Llc | $28.00 | 0.44% | 26,418 | +10,336 | +64.27% | 2025-09-30 |
| Xtx Topco Ltd | $20.00 | 0.31% | 18,775 | +18,775 | New | 2025-09-30 |
| Renaissance Technologies Llc | $13.00 | 0.2% | 11,800 | +11,800 | New | 2025-09-30 |
| Cfo4life Group, Llc | $11.00 | 0.17% | 10,461 | +10,461 | New | 2025-09-30 |
| Sbi Securities Co., Ltd. | $2.00 | 0.03% | 2,007 | +1,505 | +299.8% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.02% | 1,332 | -2,646 | -66.52% | 2025-09-30 |
| Citigroup Inc | $1.00 | 0.01% | 602 | -404 | -40.16% | 2025-09-30 |